Serum soluble IL-2 receptor as a marker of lymphocyte activation in some XXXX . Effect of immunosuppressive therapy.

@entity1 @entity8 @entity31 @entity1252 @entity30 @entity29 @entity1988 @entity1500 @entity2883 @entity34049 @entity1499 @entity792 @entity775
Our experience regarding serum soluble interleukin-2 receptor (sIL-2R) measurement as a marker of lymphocyte activation consists of @entity1 with @entity792 : 37 with @entity1252 ( @entity1252 ), 23 with @entity775 ( @entity775 ), 74 with @entity29 and six with @entity2883 ( @entity2883 ). The influence of immunosuppressive therapy has also been assessed. Serum sIL-2R in @entity1252 is significantly higher than in healthy controls and good correlation is found between sIL-2R and disease activity. Severity of @entity8 in @entity1988 can be reflected by the increased excretion of sIL-2R. It was found that sIL-2R level significantly falls when the disease becomes clinically inactive after immunosuppressive therapy, but in many cases (up to 50%) it does not reach normal levels. The last finding suggests that lymphocyte activation may still be present even though the disease is considered inactive under clinical criteria and support the need of prolonged immunosuppression after the first signs of remission. In @entity775 the serum levels of sIL-2R are elevated in all @entity1 with active disease; all cases with "highly active" disease have significantly higher concentrations than @entity1 with "mild activity". A good correlation has been demonstrated between elevated serum sIL-2R values and @entity34049 ( @entity34049 ) titer (the specific marker of @entity775 ). The follow-up study showed a significant decrease of both sIL-2R levels and anti- @entity34049 titer after 3-9 month immunosuppressive therapy. The findings support that sIL-2R and anti- @entity34049 titer could serve as reliable humoral markers for disease-specific activity. Compared with inactive @entity31 ( @entity31 ) and @entity30 ( @entity30 ), significantly higher levels of sIL-2R were present in the serum of @entity1 with active disease, and in inactive disease than in healthy age-matched controls. @entity1499 ( @entity1500 ) therapy of @entity1 with refractory @entity31 resulted in sIL-2R decrease at the end of therapeutic period (20 i.m. injections of once a week 25 mg), good responders showing > 50% decrease even at 5-7 weeks of treatment. Serum sIL-2R is elevated in all six @entity1 with @entity2883 . Contrary to anti-neutrophil cytoplasmic antibodies (ANCA), sIL-2R remains elevated above cut-off for normal range, despite clinical improvement following immunosuppressive treatment. The last observation suggests that serum sIL-2R is not a good measure of the disease activity and argue for the need of longer immunosuppressive therapy just after the first days of clinical remission.
